{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:46:06Z","timestamp":1793677566195,"version":"4.5.1"},"reference-count":100,"publisher":"American Medical Association (AMA)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2003,4,2]]},"abstract":"<jats:p>Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are associated with skeletal muscle complaints, including clinically important myositis and rhabdomyolysis, mild serum creatine kinase (CK) elevations, myalgia with and without elevated CK levels, muscle weakness, muscle cramps, and persistent myalgia and CK elevations after statin withdrawal. We performed a literature review to provide a clinical summary of statin-associated myopathy and discuss possible mediating mechanisms. We also update the US Food and Drug Administration (FDA) reports on statin-associated rhabdomyolysis. Articles on statin myopathy were identified via a PubMed search through November 2002 and articles on statin clinical trials, case series, and review articles were identified via a PubMed search through January 2003. Adverse event reports of statin-associated rhabdomyolysis were also collected from the FDA MEDWATCH database. The literature review found that reports of muscle problems during statin clinical trials are extremely rare. The FDA MEDWATCH Reporting System lists 3339 cases of statin-associated rhabdomyolysis reported between January 1, 1990, and March 31, 2002. Cerivastatin was the most commonly implicated statin. Few data are available regarding the frequency of less-serious events such as muscle pain and weakness, which may affect 1% to 5% of patients. The risk of rhabdomyolysis and other adverse effects with statin use can be exacerbated by several factors, including compromised hepatic and renal function, hypothyroidism, diabetes, and concomitant medications. Medications such as the fibrate gemfibrozil alter statin metabolism and increase statin plasma concentration. How statins injure skeletal muscle is not clear, although recent evidence suggests that statins reduce the production of small regulatory proteins that are important for myocyte maintenance.<\/jats:p>","DOI":"10.1001\/jama.289.13.1681","type":"journal-article","created":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T21:43:58Z","timestamp":1049233438000},"page":"1681","source":"Crossref","is-referenced-by-count":1102,"title":["Statin-Associated Myopathy"],"prefix":"10.1001","volume":"289","author":[{"given":"Paul D.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Clarkson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Karas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"ref-jsc20298-1","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).","volume":"344","author":"Not Available","year":"1994","journal-title":"Lancet"},{"key":"ref-jsc20298-2","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"ref-jsc20298-3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"ref-jsc20298-4","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS.","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"ref-jsc20298-5","first-page":"A10","article-title":"Bayer discloses higher death toll from Baycol.","author":"Fuhrmans","year":"2002","journal-title":"Wall Street Journal"},{"key":"ref-jsc20298-6","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1161\/01.CIR.98.9.831","article-title":"Withdrawal of Posicor from market.","volume":"98","author":"SoRelle","year":"1998","journal-title":"Circulation"},{"key":"ref-jsc20298-7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0002-9149(96)00742-4","article-title":"The efficacy and six-week tolerability of simvastatin 80 and 160 mg\/day.","volume":"79","author":"Davidson","year":"1997","journal-title":"Am J Cardiol"},{"key":"ref-jsc20298-8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis.","volume":"346","author":"Staffa","year":"2002","journal-title":"N Engl J Med"},{"key":"ref-jsc20298-11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins.","volume":"40","author":"Pasternak","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"ref-jsc20298-12","first-page":"1281","article-title":"Drug interactions and the statins.","volume":"161","author":"Herman","year":"1999","journal-title":"CMAJ"},{"key":"ref-jsc20298-13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/ki.1990.263","article-title":"Catastrophic medical events with exhaustive exercise: \"white collar rhabdomyolysis.\"","volume":"38","author":"Knochel","year":"1990","journal-title":"Kidney Int"},{"key":"ref-jsc20298-14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/anr.v32:3","article-title":"The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis.","volume":"32","author":"Goldman","year":"1989","journal-title":"Arthritis Rheum"},{"key":"ref-jsc20298-15","doi-asserted-by":"publisher","first-page":"342","DOI":"10.7326\/0003-4819-114-4-342_1","article-title":"Rhabdomyolysis and simvastatin.","volume":"114","author":"Deslypere","year":"1991","journal-title":"Ann Intern Med"},{"key":"ref-jsc20298-16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJM198801073180110","article-title":"Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.","volume":"318","author":"Norman","year":"1988","journal-title":"N Engl J Med"},{"key":"ref-jsc20298-17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1056\/NEJM198801073180111","article-title":"Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation.","volume":"318","author":"East","year":"1988","journal-title":"N Engl J Med"},{"key":"ref-jsc20298-18","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","article-title":"Lovastatin increases exercise-induced skeletal muscle injury.","volume":"46","author":"Thompson","year":"1997","journal-title":"Metabolism"},{"key":"ref-jsc20298-19","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1136\/bmj.304.6836.1225","article-title":"Rhabdomyolysis due to combined treatment with lovastatin and cholestyramine.","volume":"304","author":"Chrysanthopoulos","year":"1992","journal-title":"BMJ"},{"key":"ref-jsc20298-20","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1001\/jama.1990.03450230024013","article-title":"Increases in creatine kinase after exercise in patients treated with HMG Co-A reductase inhibitors.","volume":"264","author":"Thompson","year":"1990","journal-title":"JAMA"},{"key":"ref-jsc20298-21","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/0002-9149(91)90182-K","article-title":"Long-term safety and efficacy profile of simvastatin.","volume":"68","author":"Boccuzzi","year":"1991","journal-title":"Am J Cardiol"},{"key":"ref-jsc20298-22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2165\/00002018-200022060-00003","article-title":"HMG-CoA reductase inhibitors and myotoxicity.","volume":"22","author":"Ucar","year":"2000","journal-title":"Drug Saf"},{"key":"ref-jsc20298-23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.5694\/mja2.2001.175.issue-9","article-title":"Statin-associated myopathy.","volume":"175","author":"Hamilton-Craig","year":"2001","journal-title":"Med J Aust"},{"key":"ref-jsc20298-24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0002-9149(02)02449-9","article-title":"Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia: the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia (ExPRESS FH).","volume":"90","author":"Sauvage Nolting","year":"2002","journal-title":"Am J Cardiol"},{"key":"ref-jsc20298-25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.","volume":"360","author":"Not Available","year":"2002","journal-title":"Lancet"},{"key":"ref-jsc20298-27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels.","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"ref-jsc20298-28","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(89)91108-2","article-title":"Lovastatin, isoprenes, and myopathy.","volume":"2","author":"Walravens","year":"1989","journal-title":"Lancet"},{"key":"ref-jsc20298-29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1345\/aph.1A289","article-title":"FDA adverse event reports on statin-associated rhabdomyolysis.","volume":"36","author":"Omar","year":"2002","journal-title":"Ann Pharmacother"},{"key":"ref-jsc20298-30","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"ref-jsc20298-31","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1161\/01.CIR.89.3.959","article-title":"Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial.","volume":"89","author":"Waters","year":"1994","journal-title":"Circulation"},{"key":"ref-jsc20298-32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1056\/NEJM199701163360301","article-title":"The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.","volume":"336","author":"Post Coronary Artery Bypass Graft Trial Investigators","year":"1997","journal-title":"N Engl J Med"},{"key":"ref-jsc20298-33","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/0735-1097(95)00301-0","article-title":"Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events.","volume":"26","author":"Pitt","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"ref-jsc20298-34","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0002-9149(99)80580-3","article-title":"Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II).","volume":"75","author":"Crouse III","year":"1995","journal-title":"Am J Cardiol"},{"key":"ref-jsc20298-35","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/01.CIR.91.10.2528","article-title":"Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS).","volume":"91","author":"Jukema","year":"1995","journal-title":"Circulation"},{"key":"ref-jsc20298-36","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1161\/01.CIR.94.7.1503","article-title":"Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris.","volume":"94","author":"van Boven","year":"1996","journal-title":"Circulation"},{"key":"ref-jsc20298-37","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/0002-9149(91)90276-Q","article-title":"Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE).","volume":"68","author":"Sacks","year":"1991","journal-title":"Am J Cardiol"},{"key":"ref-jsc20298-38","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S0735-1097(97)00259-3","article-title":"Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty: Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.","volume":"30","author":"Bertrand","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"ref-jsc20298-39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0735-1097(01)01360-2","article-title":"Long-term risk stratification for survivors of acute coronary syndromes: results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study.","volume":"38","author":"Marschner","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"ref-jsc20298-40","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0002-9149(00)01230-3","article-title":"Beneficial effects of pravastatin (+\/-colestyramine\/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).","volume":"86","author":"Arntz","year":"2000","journal-title":"Am J Cardiol"},{"key":"ref-jsc20298-41","first-page":"810","article-title":"Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico)?","volume":"1","author":"GISSI Prevenzione Investigators","year":"2000","journal-title":"Ital Heart J"},{"key":"ref-jsc20298-42","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/jama.286.1.64","article-title":"Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study.","volume":"286","author":"Albert","year":"2001","journal-title":"JAMA"},{"key":"ref-jsc20298-43","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).","volume":"288","author":"Not Available","year":"2002","journal-title":"JAMA"},{"key":"ref-jsc20298-44","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"ref-jsc20298-45","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S0735-1097(01)01783-1","article-title":"Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia: Fukuoka Atherosclerosis Trial (FAST).","volume":"39","author":"Sawayama","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"ref-jsc20298-46","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/oxfordjournals.eurheartj.a015224","article-title":"The effect of simvastatin on progression of coronary artery disease: the Multicenter Coronary Intervention Study (CIS).","volume":"18","author":"Bestehorn","year":"1997","journal-title":"Eur Heart J"},{"key":"ref-jsc20298-47","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1161\/01.CIR.96.5.1398","article-title":"Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial.","volume":"96","author":"Wenke","year":"1997","journal-title":"Circulation"},{"key":"ref-jsc20298-48","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/S0002-9149(97)00346-9","article-title":"Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations: Lipoprotein and Coronary Atherosclerosis Study (LCAS).","volume":"80","author":"Herd","year":"1997","journal-title":"Am J Cardiol"},{"key":"ref-jsc20298-49","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0021-9150(99)00062-3","article-title":"The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment.","volume":"144","author":"Riegger","year":"1999","journal-title":"Atherosclerosis"},{"key":"ref-jsc20298-50","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1053\/euhj.1998.1150","article-title":"A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the Fluvastatin Angiographic Restenosis (FLARE) trial.","volume":"20","author":"Serruys","year":"1999","journal-title":"Eur Heart J"},{"key":"ref-jsc20298-51","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1046\/j.1523-1755.2001.00010.x","article-title":"Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial.","volume":"60","author":"Holdaas","year":"2001","journal-title":"Kidney Int"},{"key":"ref-jsc20298-52","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1056\/NEJM199907083410202","article-title":"Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"ref-jsc20298-53","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/S0002-9149(97)00627-9","article-title":"Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT).","volume":"80","author":"McCormick","year":"1997","journal-title":"Am J Cardiol"},{"key":"ref-jsc20298-54","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"ref-jsc20298-55","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1161\/hc2901.093188","article-title":"Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease.","volume":"104","author":"Schartl","year":"2001","journal-title":"Circulation"},{"key":"ref-jsc20298-56","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1185\/030079902125000787","article-title":"Treatment with atorvastatin to the National Cholesterol Educational Program goal versus \"usual\" care in secondary coronary heart disease prevention: the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.","volume":"18","author":"Athyros","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"ref-jsc20298-57","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1161\/01.CIR.0000046488.52939.BF","article-title":"Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function).","volume":"107","author":"Not Available","year":"2003","journal-title":"Circulation"},{"key":"ref-jsc20298-58","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1345\/aph.10228","article-title":"Rhabdomyolysis and HMG-CoA reductase inhibitors.","volume":"35","author":"Omar","year":"2001","journal-title":"Ann Pharmacother"},{"key":"ref-jsc20298-59","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1345\/aph.10315","article-title":"Statin-fibrate combination therapy.","volume":"35","author":"Shek","year":"2001","journal-title":"Ann Pharmacother"},{"key":"ref-jsc20298-60","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1001\/archinte.160.15.2273","article-title":"Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians.","volume":"160","author":"Bottorff","year":"2000","journal-title":"Arch Intern Med"},{"key":"ref-jsc20298-61","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/00041433-200212000-00007","article-title":"Safety considerations for statins.","volume":"13","author":"Bolego","year":"2002","journal-title":"Curr Opin Lipidol"},{"key":"ref-jsc20298-62","doi-asserted-by":"publisher","first-page":"37161","DOI":"10.1074\/jbc.274.52.37161","article-title":"A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transportera","volume":"274","author":"Hsiang","year":"1999","journal-title":"J Biol Chem"},{"key":"ref-jsc20298-63","first-page":"1123","article-title":"Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter.","volume":"25","author":"Yamazaki","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"ref-jsc20298-64","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0009-9236(97)90034-5","article-title":"Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses.","volume":"62","author":"Olbricht","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"ref-jsc20298-65","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/pto.2001.89.issue-3","article-title":"Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (rapamycin).","volume":"89","author":"Bramow","year":"2001","journal-title":"Pharmacol Toxicol"},{"key":"ref-jsc20298-66","first-page":"1237","article-title":"Tissue distribution of the multidrug resistance protein.","volume":"148","author":"Flens","year":"1996","journal-title":"Am J Pathol"},{"key":"ref-jsc20298-67","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.1990.03450010075034","article-title":"Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.","volume":"264","author":"Pierce","year":"1990","journal-title":"JAMA"},{"key":"ref-jsc20298-68","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1124\/dmd.30.5.505","article-title":"Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization.","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"ref-jsc20298-69","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1124\/jpet.301.3.1042","article-title":"Mechanistic studies on metabolic interactions between gemfibrozil and statins.","volume":"301","author":"Prueksaritanont","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"ref-jsc20298-70","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1124\/dmd.30.11.1280","article-title":"Effects of fibrates on metabolism of statins in human hepatocytes.","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"ref-jsc20298-71","first-page":"II185","article-title":"Metabolic interactions between gemfibrozil and statins in human liver preparations [abstract].","volume":"106","author":"Prueksaritanont","year":"2002","journal-title":"Circulation"},{"key":"ref-jsc20298-72","first-page":"258","article-title":"Statin myopathies: pathophysiologic and clinical perspectives.","volume":"24","author":"Baker","year":"2001","journal-title":"Clin Invest Med"},{"key":"ref-jsc20298-73","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1056\/NEJM196810172791604","article-title":"Acute muscular syndrome associated with administration of clofibrate.","volume":"279","author":"Langer","year":"1968","journal-title":"N Engl J Med"},{"key":"ref-jsc20298-74","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJM197704212961617","article-title":"Clofibrate-induced muscle damage with myoglobinuria and cardiomyopathy.","volume":"296","author":"Smals","year":"1977","journal-title":"N Engl J Med"},{"key":"ref-jsc20298-75","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/0002-9149(94)90453-7","article-title":"Niacin-induced myopathy.","volume":"74","author":"Gharavi","year":"1994","journal-title":"Am J Cardiol"},{"key":"ref-jsc20298-76","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1006\/taap.1997.8131","article-title":"Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.","volume":"145","author":"Flint","year":"1997","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref-jsc20298-77","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/jcph.1993.33.issue-3","article-title":"Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.","volume":"33","author":"Ghirlanda","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"ref-jsc20298-78","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/BF00194398","article-title":"Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors.","volume":"46","author":"Laaksonen","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"ref-jsc20298-79","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/0009-9236(95)90266-X","article-title":"Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans.","volume":"57","author":"Laaksonen","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"ref-jsc20298-80","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0002-9149(97)89180-1","article-title":"The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle.","volume":"77","author":"Laaksonen","year":"1996","journal-title":"Am J Cardiol"},{"key":"ref-jsc20298-81","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1046\/j.1365-2125.1996.04178.x","article-title":"Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate\/pyruvate ratio.","volume":"42","author":"De Pinieux","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"ref-jsc20298-82","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0140-6736(00)02531-9","article-title":"Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency.","volume":"356","author":"Rotig","year":"2000","journal-title":"Lancet"},{"key":"ref-jsc20298-83","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0002-9343(93)90129-D","article-title":"Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome.","volume":"94","author":"Chariot","year":"1993","journal-title":"Am J Med"},{"key":"ref-jsc20298-84","article-title":"Coenzyme Q10 with HMG-CoA reductase inhibitors. US patent 4 933 165.","author":"Brown","year":"1990"},{"key":"ref-jsc20298-85","article-title":"Coenzyme Q10 with HMG-CoA reductase inhibitors. US patent 4 929 437.","author":"Tobert","year":"1990"},{"key":"ref-jsc20298-86","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1146\/biochem.1996.65.issue-1","article-title":"Protein prenylation: molecular mechanisms and functional consequences.","volume":"65","author":"Zhang","year":"1996","journal-title":"Annu Rev Biochem"},{"key":"ref-jsc20298-87","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/sj.cdd.4400987","article-title":"Rho GTPase signalling pathways in the morphological changes associated with apoptosis.","volume":"9","author":"Coleman","year":"2002","journal-title":"Cell Death Differ"},{"key":"ref-jsc20298-88","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1126\/science.7652575","article-title":"An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1.","volume":"269","author":"Olson","year":"1995","journal-title":"Science"},{"key":"ref-jsc20298-89","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/jcp.v192:2","article-title":"Ras family genes: an interesting link between cell cycle and cancer.","volume":"192","author":"Macaluso","year":"2002","journal-title":"J Cell Physiol"},{"key":"ref-jsc20298-90","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1161\/01.RES.83.5.490","article-title":"3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture.","volume":"83","author":"Guijarro","year":"1998","journal-title":"Circ Res"},{"key":"ref-jsc20298-91","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0021-9150(99)00462-1","article-title":"Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death.","volume":"152","author":"Knapp","year":"2000","journal-title":"Atherosclerosis"},{"key":"ref-jsc20298-92","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S0022-2275(20)37182-0","article-title":"Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts.","volume":"38","author":"Matzno","year":"1997","journal-title":"J Lipid Res"},{"issue":"Pt 1","key":"ref-jsc20298-93","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1469-7793.2001.00155.x","article-title":"Effects of concentric and eccentric contractions on phosphorylation of MAPK(erk1\/2) and MAPK(p38) in isolated rat skeletal muscle.","volume":"535","author":"Wretman","year":"2001","journal-title":"J Physiol"},{"key":"ref-jsc20298-94","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s004240000417","article-title":"Influence of exercise intensity on ERK\/MAP kinase signalling in human skeletal muscle.","volume":"441","author":"Widegren","year":"2000","journal-title":"Pflugers Arch"},{"key":"ref-jsc20298-95","first-page":"1089","article-title":"Intraoperative rhabdomyolysis in a patient receiving pravastatin, a 3 hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor.","volume":"81","author":"Rosenberg","year":"1995","journal-title":"Anesth Analg"},{"key":"ref-jsc20298-96","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1001\/jama.1989.03430010065032","article-title":"Effects of cyclosporine therapy on plasma lipoprotein levels.","volume":"262","author":"Ballantyne","year":"1989","journal-title":"JAMA"},{"key":"ref-jsc20298-97","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1046\/j.1525-1497.2002.20201.x","article-title":"Evaluation and management of dyslipidemia in patients with HIV infection.","volume":"17","author":"Green","year":"2002","journal-title":"J Gen Intern Med"},{"key":"ref-jsc20298-99","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0735-1097(02)02610-4","article-title":"Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.","volume":"40","author":"Davidson","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"ref-jsc20298-100","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).","volume":"285","author":"Not Available","year":"2001","journal-title":"JAMA"},{"key":"ref-jsc20298-9","volume-title":"Cardiovascular Trials Review","author":"Not Available","year":"2001","edition":"6th ed."},{"key":"ref-jsc20298-10","volume-title":"Cardiovascular Trials Review","author":"Not Available","year":"2002","edition":"7th ed."},{"key":"ref-jsc20298-26","volume-title":"Physicians' Desk Reference","author":"Not Available","year":"2002","edition":"56th ed."},{"key":"ref-jsc20298-98","first-page":"2126","volume-title":"Physicians' Desk Reference","author":"Not Available","year":"2003"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/196305\/jsc20298_1681_1690_1706737352.55756.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T22:30:35Z","timestamp":1706740235000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/196305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,2]]},"references-count":100,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2003,4,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.289.13.1681","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2003,4,2]]}}}